Dr. Tara O'Donohue, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Expert in Tumors
Studies Brain Tumor
13 reported clinical trials
22 drugs studied
Area of expertise
1Tumors
Global LeaderNTRK positive
Stage IV
ALK positive
2Brain Tumor
NTRK positive
Stage IV
ALK positive
Affiliated Hospitals
Clinical Trials Tara O'Donohue, MD is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Ensartinib
for Cancer
This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment (refractory) and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 217 criteria
More about Tara O'Donohue, MD
Clinical Trial Related7 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Tara O'Donohue, MD has experience with
- Repotrectinib
- Larotrectinib
- Selpercatinib
- Tipifarnib
- Irinotecan And Temozolomide
- Neratinib
Breakdown of trials Tara O'Donohue, MD has run
Tumors
Brain Tumor
Lymphoma
Osteosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tara O'Donohue, MD specialize in?
Tara O'Donohue, MD focuses on Tumors and Brain Tumor. In particular, much of their work with Tumors has involved NTRK positive patients, or patients who are Stage IV.
Is Tara O'Donohue, MD currently recruiting for clinical trials?
Yes, Tara O'Donohue, MD is currently recruiting for 5 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Tara O'Donohue, MD has studied deeply?
Yes, Tara O'Donohue, MD has studied treatments such as Repotrectinib, Larotrectinib, Selpercatinib.
What is the best way to schedule an appointment with Tara O'Donohue, MD?
Apply for one of the trials that Tara O'Donohue, MD is conducting.
What is the office address of Tara O'Donohue, MD?
The office of Tara O'Donohue, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.